Blog2014-10-11T14:23:15+00:00

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

By |November 29th, 2021|Categories: Events|

More Information

Go to Top